NCT06433999View on ClinicalTrials.gov

A 12-Week Open-Label Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With Skin-Predominant Dermatomyositis

PHASE2CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

August 28, 2024

Primary Completion Date

February 28, 2025

Study Completion Date

February 28, 2025

Conditions
DermatomyositisDermatomyositis, Adult Type
Interventions
DRUG

Brepocitinib

Oral Brepocitinib PO QD

Trial Locations (1)

85259

Clinical Trial Site, Scottsdale

Sponsors
All Listed Sponsors
lead

Priovant Therapeutics, Inc.

INDUSTRY